Books > Science & Mathematics > Biology, life sciences > Life sciences: general issues > Genetics (non-medical)
|
Not currently available
Preponderance Of Low Vision And Blindness In Rp Patients Of Okara (Paperback)
Loot Price: R1,307
Discovery Miles 13 070
|
|
Preponderance Of Low Vision And Blindness In Rp Patients Of Okara (Paperback)
Supplier out of stock. If you add this item to your wish list we will let you know when it becomes available.
|
We performed a retrospective study between December 2010 and May
2011 on all retinitis pigmentosa (RP) cases seen from Okara during
ophthalmological consultation at Lyton Rahmatullah Benevolent trust
(LRBT) hospital from August 2008 to January 2011. The aim of this
study was to determine the preponderance of low vision and
blindness in retinitis pigmentosa in patients of Okara. The
techniques used for the diagnosis of retinitis pigmentosa were an
examination of ocular fundus using a biomicroscope (fundoscopy),
far visual acuity and visual field. Indeed, a drop in visual acuity
and blindness were the main reasons for consultation in this study.
100 cases were reported of which two were with family history from
Okara, 70 male and 30 females were affected from RP. The average
age of RP patients was 27.45 with a range of 4-78 years. Blindness
and low vision was observed in 54% of the patients and 40%
respectively. The average age of RP patients with low vision ranges
from 6-50 years and the average age of RP patients with blindness
range from 9-65 years. Patients should be screened to enable them
to benefit from management focusing on both appropriate treatment
and genetic counseling.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.